Office of Commercialization and Economic Development
Office of Technology Commercialization

Subunit Vaccine Against Dengue Virus

Technology #20-0009

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Brian Kuhlman
Managed By
Kyle Bartholomew
Commercialization Manager 919.962.5921
Patent Protection
PCT Patent Application Filed

Current approaches to Dengue Virus (DENV) vaccine design all make use of live attenuated viruses. This appraoch suffers from difficulties in desinging a vaccine formulation that can eleicit a balanced immune response against all four serotypes of DENV. Subunit vaccines, composed only of the immungenic E protein found on the surface of the DENV viral capsid, present an alternative appraoch to live attenuated vaccines; however, this appraoch has not been widley tested because it is difficult to express the DENV E protein in dimer form. Our invetigators have developed mutant Dengue E proteins that are stable as dimers in solution, and that can be used in a subunit DENV vaccine that targets all four DENV serotypes.

Related Publications: